Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (2023 - 2026)

Contineum Therapeutics' Shares Outstanding history spans 4 years, with the latest figure at $32.7 million for Q1 2026.

  • Quarterly Shares Outstanding rose 70.95% to $32.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $32.7 million through Mar 2026, up 70.95% year-over-year, with the annual reading at $31.2 million for FY2025, 364.2% up from the prior year.
  • Shares Outstanding came in at $32.7 million for Q1 2026, down from $37.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $37.3 million in Q4 2025 to a low of $2.3 million in Q1 2023.
  • The 4-year median for Shares Outstanding is $22.4 million (2024), against an average of $19.9 million.
  • Year-over-year, Shares Outstanding skyrocketed 714.98% in 2024 and then grew 19.78% in 2025.
  • Contineum Therapeutics' Shares Outstanding stood at $2.3 million in 2023, then surged by 186.4% to $6.7 million in 2024, then surged by 364.2% to $31.2 million in 2025, then grew by 4.76% to $32.7 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Shares Outstanding are $32.7 million (Q1 2026), $31.2 million (Q4 2025), and $22.8 million (Q3 2025).